Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Most patients with advanced ovarian cancer suffered recurrences. Therefore, adjuvant therapy
is recommended for all patients with advanced ovarian cancer.
Traditionally, intravenous paclitaxel + carboplatin has been the standard adjuvant therapy.
Recently, intraperitoneal combination chemotherapy has been reported to be effective in
ovarian cancer.
We attempted to evaluate the efficacy and feasibility of standard intravenous paclitaxel +
carboplatin plus intraperitoneal paclitaxel chemotherapy.